Eli Lilly's $7 billion deal for Kelonia Therapeutics on Monday was just the latest example of the sky-high prices that Big Pharmas are willing to pay for in vivo CAR-T tech. In fact, it was the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results